重磅降脂药恒瑞获批!信达、康方、君实之后,齐鲁、石药等全面参战

医药经济报
18 Jan

PCSK9作为降脂药物领域的核心赛道,不仅成为各大MNC激烈争夺的高地,更促使国内药企全面加快研发步伐,力图在这场没有硝烟的战争中抢占先机!近日,恒瑞医药子公司广东恒瑞医药有限公司收到国家药品监督管理局(NMPA)核准签发的《药品注册证书》,批准公司自主研发的1类创新药、超长效PCSK9单抗瑞卡西单抗(商品名:艾心安®)上市。值得关注的是,瑞卡西单抗是恒瑞医药在心血管疾病领域上市的首个1类创新药,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10